“It was hypothesized that NEB, a β1-AR antagonist and β3-AR agonist with NO-releasing properties, and MET , only a β1-AR antagonist, would have different effects on plasma asymmetric dimethylarginine ( ADMA ) concentration.”
“Plasma ADMA and augmentation index are increased in a dose-dependent fashion by MET but not with NEB.”